The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

Pluvicto is currently approved for metastatic castration-resistant prostate cancer (mCRPC). Given that nearly all mHSPC patients eventually progress to mCRPC, these new data suggest its potential ...

Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...